David S. Ivill is a partner in the law firm of McDermott Will & Emery LLP and is based in the Firm’s New York office. He is the partner-in-charge of the Health Industry Advisory practice in New York. David has extensive experience in statutory and regulatory issues affecting the provision of health care services, particularly with respect to New York State; his practice includes counseling with respect to operational and management issues, fraud and abuse, Medicaid Managed Care, compliance programs, as well as reimbursement matters, corporate practice of medicine issues and not-for-profit/tax-exempt matters. David also has significant experience working with federally qualified health centers and advising clients with respect to the 340B Federal Drug Pricing Program. He represents a range of health care providers including hospitals, physicians and rehabilitation agencies, as well as other health care entities including clinical laboratories and medical device manufacturers. David represents Patient Safety Organizations (PSO) and has developed some of the first PSOs in the country. He also has private equity and mergers and acquisitions experience.
David is listed in Best Lawyers in America and has been recognized by Chambers USA as one of the leading lawyers in his field. He is a member of the American Health Lawyers Association and the Bar of the City of New York.
Prior to practicing law, David was a podiatric surgeon specializing in foot and ankle reconstruction with a subspecialty in oteomyelitis of the lower extremity.
More Legal and Business Bylines From David S. Ivill
- New York Proposes Regulatory Review of Physician Practice Transactions - (Posted On Friday, February 17, 2023)
- The Practical Import of the Carothers Decision on New York Practice Management Arrangements - (Posted On Wednesday, April 19, 2017)
- 340B Program Rules to Remain Unclear - (Posted On Thursday, February 02, 2017)
- HHS Proposes Administrative Dispute Resolution Process for 340B-Related Claims - (Posted On Tuesday, August 16, 2016)
- OIG Reports on, Proposes Alternatives to Medicare Part B Reimbursement for 340B Drugs - (Posted On Monday, December 07, 2015)
- D.C. Federal Court Rejects HHS Interpretation of 340B Program’s Orphan Drug Rule - (Posted On Tuesday, October 20, 2015)
- Proposed Rules Released Covering 340B Ceiling Prices and Manufacturer Penalties - (Posted On Wednesday, June 17, 2015)
- House Subcommittee Circulates Proposed Legislation Providing Insight on the Future of the 340B Drug Pricing Program - (Posted On Tuesday, May 26, 2015)
- 340B ‘Mega-Guidance’ Arrives at Office of Management and Budget - (Posted On Thursday, May 07, 2015)
- Health Resources and Services Administration (HRSA) Withdraws 340B Program Proposed Rule - (Posted On Thursday, November 20, 2014)